News | May 27, 2007

Abbott Recalls ARCHITECT STAT Troponin-I Test

May 29, 2007 — Abbott announced Friday, May 25, that it has initiated a voluntary, nationwide recall of its ARCHITECT STAT Troponin-I diagnostic test. The product was distributed to clinical laboratories both in the U.S. and abroad, and is used to aid in the diagnosis of injury to heart muscle and/or heart attack.

No patient injuries have been reported. Laboratories may continue to use the product with the updated directions for use, which Abbott is distributing to clinical labs.

The additional instructions provide that: (a) for laboratories or physicians using 0.1 ng/mL or less than 0.1 ng/mL as the cut-off, samples should be retested and/or serial negative blood draws over time should be evaluated before patients are classified as negative for a heart attack; (b) recent negative results less than 0.1 ng/mL should also be re-evaluated and the ordering physicians should be notified; (c) laboratory reports of negative patient results less than 0.1 ng/mL should contain the cautionary language contained in (a) and (b) above.

Abbott previously issued a product correction notice to customers explaining the issue and advising them to evaluate and adjust the reference ranges used in their laboratory when running this test.

Abbott has identified the root cause and is working on correcting the issue — the company has reported the action to the FDA. No other ARCHITECT assays or Abbott instruments are affected.

A Troponin-I test is usually ordered, along with other cardiac tests, in the hospital to determine if a patient has had a heart attack or other injury to heart muscle. The test, conducted using a sample of the patient's blood, aids in the diagnosis of myocardial injury or infarction. The results of Troponin-I tests should be used in conjunction with other diagnostic information including other cardiac markers, ECG, clinical observations and symptoms. As with any diagnostic test, Abbott recommends in its product labeling that results from the ARCHITECT STAT Troponin-I test be interpreted in conjunction with other clinical and laboratory findings.

Clinical laboratory customers with questions may contact the company at 1-877-4ABBOTT.

For more information visit www.fda.gov/medwatch/report.htm and www.abbott.com.

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Catheters| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance of coronary lesions to determine if they should be revas
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Overlay Init